Lymphodepletion (LD), tumor-infiltrating lymphocytes (TIL) and high (HD-IL2) versus low-dose (LD-IL2) IL-2 followed by pembrolizumab (pembro) in patients (pts) with metastatic melanoma (MM).
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Rodabe Navroze Amaria, Cara L. Haymaker, Marie-Andree Forget, Roland Bassett, Janice N. Cormier, Michael A. Davies, Adi Diab, Jeffrey E. Gershenwald, Isabella Claudia Glitza, Jeffrey Edwin Lee, Anthony Lucci, Jennifer Leigh McQuade, Sapna Pradyuman Patel, Richard Eldon Royal, Merrick I. Ross, Hussein Abdul-Hassan Tawbi, Jennifer Ann Wargo, Michael K.K. Wong, Chantale Bernatchez, Patrick Hwu
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2947003661